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Filoviruses such as Ebola (EBOV) and Marburg (MARV) viruses cause deadly viral hemorrhagic fever in 
humans with high case fatality rates. To date, no licenced therapeutic or vaccine has been clinically approved to 
prevent infection. Several vaccine candidates are under development against the few most common filoviruses 
targeting the virus glycoprotein (GP). However, protective antibodies induced by such GP vaccines are usually 
limited to the same species. In contrast, T-cell vaccines offer an opportunity to design a single pan-filovirus 
vaccine protecting against all members of the Filoviridae family. In this study FILOcepX vaccines were 
constructed targeting the four most conserved regions among the viral proteomes with the aim to induce 
protective T-cell responses against different filoviruses. BALB/c mice were immunized with FILOcep 1 and 2 
vaccines vectored by non-replicating engineered simian adenovirus and poxvirus MVA. Groups of 20 BALB/c 
mice were primed and boosted with either the FILOcep1 and FILOcep2 vaccines or control ChAdOx1- and 
MVA-vectored vaccines. Four animals in each group were sacrificed after 1 week of boosting to detect T-cell 
response for the FILOcepX antigen. High frequency T cells specific responses were detected in mice receiving 
the test vaccines by IFN-γ ELISPOT kits. Of the remaining 16 animals in each group, 8 were challenged with 
mouse-adapted EBOV and 8 were challenged with mouse adapted MARV in Containment Level 4 laboratory. All 
the mice in the control group either died or had to be euthanized between 4 and 6 days post challenge. On the 
other hand all the FILOcepX vaccinated mice maintained their normal body mass and survived till the end of the 
scheduled protocol on day 29 post challenge. These FILOcepX vaccines provided 100% protection against the 
lethal challenges with filoviruses of two different genera. Further evaluation the efficacy of this vaccine in non-
human primates (NHPs) is warranted. 
 
